Wire · opportunities
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA approved finerenone (Kerendia) to reduce urinary albumin-to-creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes, marking the first new treatment advance in over 30 years for this condition. This approval is based on the FINE-ONE Phase 3 trial showing significant reduction in markers associated with kidney disease progression and includes safety monitoring for hyperkalemia.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You can target a clinical gap ignored for 30 years with the first new approved treatment for kidney disease in type 1 diabetes. This opens patient pathways previously unreachable and demands you factor in finerenone's safety profile, especially potassium monitoring.
◆ Coverage
5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics